Copyright © 2019. Inderes Oy. All rights reserved.

Faron Pharmaceuticals


Sisäpiirin kaupat



TURKU - FINLAND, 23 November 2020  - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announced that management will participate in the following virtual investor conferences:

  • 32nd Annual Piper Sandler Virtual Healthcare Conference

Pre-recorded fireside chat available on-demand starting Monday, 23 November 2020 at 10:00 a.m. ET

  • 3rd Annual Evercore ISI HealthCONx Conference
Fireside Chat on Wednesday, 2 December 2020 at 8:25 a.m. ET

Faron Pharmaceuticals

Faron Pharmaceuticals

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the endothelial receptors involved in regulation of immune response, in oncology and organ damage.

Our pipeline consists of two drug candidates and development programmes Clevegen (FP-1305) and Traumakine (FP-1201-lyo). Clevegen aims to tackle several cancer types by activating immunity; Traumakine organ trauma and vascular damage by stopping vascular leakage. Both programmes have advanced to first-in-human clinical trials following promising pre-clinical data. 

Faron is based in Turku, Finland. Further information is available at